Analysts Set Medpace Holdings, Inc. (NASDAQ:MEDP) PT at $487.36

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been assigned a consensus rating of “Hold” from the fourteen analysts that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $483.4545.

Several equities analysts recently commented on the company. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a report on Tuesday, February 10th. Leerink Partners lowered their target price on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Finally, Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th.

Insider Buying and Selling at Medpace

In other news, CFO Kevin M. Brady sold 3,000 shares of the stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the transaction, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $3,542,100. This represents a 33.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction on Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the sale, the chief executive officer owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. This trade represents a 7.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 226,603 shares of company stock valued at $137,084,658 in the last three months. Corporate insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

Large investors have recently modified their holdings of the stock. AQR Capital Management LLC grew its stake in Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after buying an additional 324,293 shares during the last quarter. Wasatch Advisors LP grew its position in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the last quarter. Mawer Investment Management Ltd. increased its holdings in shares of Medpace by 17.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after acquiring an additional 121,213 shares during the period. Geode Capital Management LLC lifted its position in Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Finally, Baillie Gifford & Co. boosted its stake in Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after purchasing an additional 62,503 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Medpace stock opened at $446.17 on Monday. Medpace has a 1 year low of $250.05 and a 1 year high of $628.92. The firm has a 50 day moving average price of $560.49 and a 200 day moving average price of $538.45. The company has a market cap of $12.66 billion, a price-to-earnings ratio of 29.16, a PEG ratio of 2.05 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. During the same period last year, the business posted $3.67 EPS. The company’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts predict that Medpace will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.